GlassScriptPhysician profile
Mary A Pegan
NPI 1366173114
$2,396.96
in general payments reported to CMS, 2019-2025
29 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $374 · 2023: $872 · 2024: $799 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $444.59 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $377.41 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $247.04 | 2022-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Astrazeneca Pharmaceuticals LP | $162.25 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.77 | 2022-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $137.72 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.21 | 2022-2025 | Trintellix, Glassia |
| Glaxosmithkline, LLC. | $85.33 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $76.17 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $64.35 | 2023-2024 | Rexulti |
| Pfizer INC. | $57.42 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $51.70 | 2023 | Hetlioz |
| Edwards Lifesciences Corporation | $48.85 | 2024-2025 | Sapien 3 Ultra Resilia |
| Paratek Pharmaceuticals, INC. | $46.99 | 2022-2024 | Nuzyra |
| Exact Sciences Corporation | $42.09 | 2024 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $33.54 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $33.53 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.98 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $24.08 | 2022 | |
| Corcept Therapeutics | $21.04 | 2025 | Korlym |
| Verona Pharma, INC. | $20.88 | 2025 | Ohtuvayre |
| Cumberland Pharmaceuticals, INC. | $20.85 | 2024 | Kristalose |
| Novartis Pharmaceuticals Corporation | $19.48 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.56 | 2022 | |
| Mylan Specialty L.P. | $17.35 | 2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $16.57 | 2024 | |
| Phathom Pharmaceuticals, INC. | $16.18 | 2024 | Voquezna |
| Ibsa Pharma INC. | $14.41 | 2024 | Flector, Tirosint, Licart |
| Amarin Pharma, INC. | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Pegan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.